Legend Biotech Corporation (LEGN)
LEGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LEGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001801198 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0B |
| Net income | -$296.8M |
| Operating income | -$136.5M |
| Net margin | -28.8% |
| Operating margin | -13.3% |
| Revenue growth | +64.0% |
| Cash | $901.9M |
| Total assets | $1.7B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Our prior losses and any future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our common shares and may in the future raise substantial doubt about our ability to continue as a going concern." | 20-F 2026-03-10 |
| Cash and burn | $901.9M cash; operating cash flow -$25.1M a quarter. | Report 2025-12-31 |
| Shares outstanding | 184,943,185 (2025-12-31); 183,649,158 a year earlier; 165,067,240 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $308K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $1.0B | -$296.8M | -$100.2M | $901.9M | $319.1M | $1.0B | 20-F 2026-03-10 |
| FY 2024 2024-12-31 | $627.2M | -$177.0M | -$144.0M | $286.7M | $250.0M | $627.2M | 20-F 2025-03-11 |
| FY 2023 2023-12-31 | $285.1M | -$518.3M | -$393.3M | $1.3B | $250.0M | $285.1M | 20-F 2025-03-11 |
| FY 2022 2022-12-31 | $117.0M | -$446.3M | -$201.3M | $786.0M | $250.0M | $117.0M | 20-F 2025-03-11 |
| FY 2021 2021-12-31 | $68.8M | -$403.6M | -$198.5M | $688.9M | $119.7M | $68.8M | 20-F 2024-03-19 |
| FY 2020 2020-12-31 | $75.0M | -$266.4M | -$223.0M | $455.7M | No debt tags | $75.0M | 20-F 2023-03-30 |
| FY 2019 2019-12-31 | $60.0M | -$101.6M | -$83.1M | $83.4M | No debt tags | $60.0M | 20-F/A 2023-02-17 |
| FY 2018 2018-12-31 | $49.1M | -$2.8M | $307.7M | $210.2M | No debt tags | $49.1M | 20-F 2021-04-02 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-18 |
| Latest annual report | 20-F | 2026-03-10 |
| Latest quarterly / interim | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 388 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -25.2% |
| 1 month | -2.1% |
| 3 months | -13.7% |
| Year to date | -19.5% |
| 1 year | -43.6% |
| From 52-week high | -51.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DYN | Dyne Therapeutics Inc. | $16.70 | -2.68% | $3.1B |
| BHC | Bausch Health Companies Inc. | $8.42 | +0.84% | $3.2B |
| XERS | Xeris Biopharma Holdings Inc. | $16.70 | +0.24% | $3.1B |
| TLX | Telix Pharmaceuticals Limited | $8.92 | -3.36% | $3.0B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.67 | -0.43% | $3.2B |
| IDYA | IDEAYA Biosciences Inc. | $30.36 | -4.62% | $2.9B |
| VCRE | Vicore Pharma Holding AB | $10.16 | -1.93% | $2.9B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier